Nifty99000 100%

Sensex99000 100%


Diabetes, cancer drug prices slashed by up to 80%

Author: S Vijaykrishnan/Tuesday, March 7, 2017/Categories: Healthcare

Diabetes, cancer drug prices slashed by up to 80%

New Delhi (IANS) - There has been "significant price reduction" in major cancer and diabetic drugs over the past year as a measure of relief to patients in the country, the National Pharmaceutical Pricing Authority (NPPA) said. The drug prices regulator, in a tweet, said that since March 2016, there has been "significant price reduction" by up to 86% in some major cancer drugs, and by up to 42% in major diabetic drugs.
 Among the major cancer drugs, the price of Iressa of Astrazeneca Pharma India, which cost Rs 29,259 (before revision), has been cut down by 86% to Rs 3,977.
 The prices of other important cancer drugs, such as Nanoxel (Rs 1,035) and Frastim (Rs 1,273) have been slashed by 55% and 51% respectively.
 In terms of diabetic drugs, Glypride by Sun Pharmaceuticals has been priced at Rs 53 - down 42% from Rs 91.
 As per the NPPA, other pharma firms whose drug prices have been revised downwards are Dr Reddy's Lab,  Abbot Healthcare, Micro Labs, Dabur India, Lupin and others.

Print Rate this article:
No rating

Number of views (92)/Comments (0)

S Vijaykrishnan
S Vijaykrishnan

S Vijaykrishnan

Other posts by S Vijaykrishnan
Contact author

Leave a comment

Add comment



Ask the Finapolis.

I'm not a robot
Dharmendra Satpathy
Col. Sanjeev Govila (retd)
Hum Fauji Investments
The Finapolis' expert answers your queries on investments, taxation and personal finance. Want advice? Submit your Question above
Want to Invest



The technical studies / analysis discussed here can be at odds with our fundamental views / analysis. The information and views presented in this report are prepared by Karvy Consultants Limited. The information contained herein is based on our analysis and upon sources that we consider reliable. We, however, do not vouch for the accuracy or the completeness thereof. This material is for personal information and we are not responsible for any loss incurred based upon it. The investments discussed or recommended in this report may not be suitable for all investors. Investors must make their own investment decisions based on their specific investment objectives and financial position and using such independent advice, as they believe necessary. While acting upon any information or analysis mentioned in this report, investors may please note that neither Karvy nor Karvy Consultants nor any person connected with any associate companies of Karvy accepts any liability arising from the use of this information and views mentioned in this document. The author, directors and other employees of Karvy and its affiliates may hold long or short positions in the above mentioned companies from time to time. Every employee of Karvy and its associate companies is required to disclose his/her individual stock holdings and details of trades, if any, that they undertake. The team rendering corporate analysis and investment recommendations are restricted in purchasing/selling of shares or other securities till such a time this recommendation has either been displayed or has been forwarded to clients of Karvy. All employees are further restricted to place orders only through Karvy Consultants Ltd. This report is intended for a restricted audience and we are not soliciting any action based on it. Neither the information nor any opinion expressed herein constitutes an offer or an invitation to make an offer, to buy or sell any securities, or any options, futures or other derivatives related to such securities.